** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals 260y.F, CNTA.O with "buy" rating

** Brokerage says co's experimental drug, ORX750, is "best-in-class" for treating excessive daytime sleepiness (EDS)

** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night

** Notes ORX750 "restored wakefulness at low doses with clean safety" in early-stage trial

** Brokerage says ORX750 demonstrated "higher potency and OX2R selectivity" compared with competitors in early development

** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness

** All 9 brokerages rate stock "buy" or higher; their median PT is $27 - LSEG data

** Stock more than doubled in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))